Intermountain Heart Institute, Intermountain Medical Center, Murray, Utah 84107, USA.
Heart Rhythm. 2013 Sep;10(9):1272-7. doi: 10.1016/j.hrthm.2013.07.002. Epub 2013 Jul 5.
Atrial fibrillation (AF) is a leading cause of total and fatal ischemic stroke. Stroke risk after AF ablation appears to be favorably affected; however, it is largely unknown whether the benefit extends to all stroke CHADS2 risk profiles of AF patients.
To determine if ablation of atrial fibrillation reduces stroke rates in all risk groups.
A total of 4212 consecutive patients who underwent AF ablation were compared (1:4) with 16,848 age-/sex-matched controls with AF (no ablation) and to 16,848 age-/sex-matched controls without AF. Patients were enrolled from the large ongoing prospective Intermountain Atrial Fibrillation Study and were followed for at least 3 years.
Of the 37,908 patients, the mean age was 65.0 ± 13 years and 4.4% (no AF), 6.3% (AF, no ablation), and 4.5% (AF ablation) patients had a prior stroke (P < .0001). The profile of CHADS2 scores between comparative groups was similar: 0-1 (69.3%, no AF; 62.3%, AF, no ablation; 63.6%, AF ablation), 2-3 (26.5%, no AF; 29.7%, AF, no ablation; 28.7%, AF ablation), and ≥4 (4.3%, no AF; 8.0%, AF, no ablation; 7.7%, AF ablation). A total of 1296 (3.4%) patients had a stroke over the follow-up period. Across all CHADS2 profiles and ages, AF patients with ablation had a lower long-term risk of stroke compared to patients without ablation. Furthermore, AF ablation patients had similar long-term risks of stroke across all CHADS2 profiles and ages compared to patients with no history of AF.
In our study populations, AF ablation patients have a significantly lower risk of stroke compared to AF patients who do not undergo ablation independent of baseline stroke risk score.
心房颤动(AF)是总发病率和致死性缺血性卒中的主要原因。AF 消融后的卒中风险似乎得到了有利影响;然而,AF 患者的所有卒中 CHADS2 风险谱是否都能从中获益,目前尚不清楚。
确定 AF 消融是否能降低所有风险组的卒中发生率。
共比较了 4212 例连续接受 AF 消融的患者(1:4)和 16848 例年龄/性别匹配的有 AF(无消融)患者及 16848 例年龄/性别匹配的无 AF 患者。患者来自大型前瞻性 Intermountain Atrial Fibrillation 研究,随访至少 3 年。
在 37908 例患者中,平均年龄为 65.0 ± 13 岁,4.4%(无 AF)、6.3%(AF,无消融)和 4.5%(AF 消融)的患者有既往卒中(P<0.0001)。比较组间 CHADS2 评分的分布相似:0-1(69.3%,无 AF;62.3%,AF,无消融;63.6%,AF 消融)、2-3(26.5%,无 AF;29.7%,AF,无消融;28.7%,AF 消融)和≥4(4.3%,无 AF;8.0%,AF,无消融;7.7%,AF 消融)。随访期间共有 1296 例(3.4%)患者发生卒中。在所有 CHADS2 评分和年龄组中,与未消融的患者相比,消融的 AF 患者发生长期卒中的风险较低。此外,在所有 CHADS2 评分和年龄组中,与无 AF 史的患者相比,AF 消融患者的长期卒中风险相似。
在我们的研究人群中,与未接受消融的 AF 患者相比,AF 消融患者的卒中风险显著降低,且独立于基线卒中风险评分。